The most effective intravesical regimen for the treatment of non-muscle invasive bladder cancer (NMIBC) refractory to Bacillus Calmette-Guérin (BCG) has still not been identified or optimized to minimize recurrence-free survival and prevent progression reliably and consistently.
Valrubicin, however, is a cytotoxic chemotherapeutic agent that is used as an intravesical agent for BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. Here we analyze the literature regarding the treatment of non-muscle invasive urothelial malignancies with intravesical valrubicin for refractory bladder cancer, present our opinion on its current clinical impact and speculate on how its utilization will evolve in the near future.
Expert review of anticancer therapy. 2015 Nov 16 [Epub ahead of print]
Pranav Sharma, Kamran Zargar-Shoshtari, Wade J Sexton
a Department of Genitourinary Oncology , Moffitt Cancer Center , Tampa , FL , USA. , a Department of Genitourinary Oncology , Moffitt Cancer Center , Tampa , FL , USA. , a Department of Genitourinary Oncology , Moffitt Cancer Center , Tampa , FL , USA.